Shawn S.‐C. Li

This study shows that inhibiting LIN28A with LIN28i-1632 enhances imatinib sensitivity in imatinib-resistant CML cells by reducing BCR-ABL abundance and disrupting the AKT survival pathway.

This study identifies LIN28A as a mediator of imatinib resistance in CML by reprogramming the kinome and phosphoproteome, with potential therapeutic implications for overcoming resistance.

This study shows that inhibiting PU.1 in mice reduces tumor growth by increasing cytotoxic lymphocyte recruitment via the CXCL9-CXCR3 axis.

MMS2plot is an R package that visualizes MS/MS spectra for modified and non-modified peptides to aid in PTM assignment.